Executive Summary

The global medical technology (medtech) market is undergoing a profound structural transformation. In 2026, five interconnected trends are expected to redefine how companies compete across pricing, care delivery, manufacturing, and innovation. These forces extend well beyond any single therapy area or geography, and their combined effect will shape investment decisions, portfolio strategies, and long-term market positioning for years to come.

Medical device manufacturers that already rely on mature product lines and established relationships with hospital procurement departments are finding that traditional models are no longer sufficient. The accelerating influence of value-based procurement, the migration of surgeries to ambulatory settings, and the integration of data-driven platforms are forcing a fundamental reassessment of what constitutes competitive advantage in this industry.

Introduction: The Medtech Landscape in Transition

For decades, the medtech industry was characterized by incremental innovation, steady procedure volumes, and a relatively predictable reimbursement environment. That era is ending. The convergence of regulatory shifts, macroeconomic pressures, and technological change has created a landscape where agility and strategic foresight are as important as clinical efficacy.

This article examines five key trends outlined in a recent report by Clarivate, a global intelligence provider, and situates them within the broader business context. These trends are not isolated events but signals of a deeper reordering of the economic and operational assumptions that have governed the industry since the early 2000s. Understanding them is essential for executives, investors, and policymakers seeking to navigate the next phase of medtech's evolution.

Business Context: The Forces Converging on Medical Technology

Medical technology sits at the intersection of healthcare, advanced manufacturing, and digital innovation. Its global market size is estimated at over $500 billion, with growth historically buoyed by aging populations, rising chronic disease prevalence, and technological advancement. However, the industry is now facing cost-containment pressures from governments and insurers, heightened scrutiny over clinical value, and competition from new entrants leveraging artificial intelligence and robotics.

Into this context, the five trends identified in Clarivate's forthcoming Medtech Trends to Watch 2026 report inject further complexity. Each trend alters the calculus for market participation, and together they constitute what could be called a new operating system for the industry.

Main Analysis: Five Trends Reshaping the Industry

1. China's Volume-Based Procurement: A New Global Pricing Benchmark

Mainland China's volume-based procurement (VBP) program is no longer merely a domestic pricing policy; it has become a global reference point for how medical devices are valued. The latest round of VBP introduced more sophisticated anchor-price mechanisms, deeper price reductions, and allocation systems that favor domestic manufacturers. For multinational companies, this means that selling in China increasingly requires acceptance of pricing levels that could be used as benchmarks in other markets, even where regulatory and demand conditions differ.

The strategic implications are twofold. First, multinational medtech firms must decide whether to compete aggressively in China—accepting lower margins in exchange for market access and scale—or to pivot toward higher-value niches where their technologies can justify premium pricing. Second, the shift is accelerating domestic Chinese innovation, as local companies gain market share and reinvest in R&D. This mirrors patterns seen in other industries, such as telecommunications and electric vehicles, where local champions eventually become global competitors.

2. The Outpatient Migration: Site of Care as a Strategic Variable

The U.S. Centers for Medicare & Medicaid Services (CMS) has increasingly expanded the list of procedures eligible for ambulatory surgical centers (ASCs) and hospital outpatient departments. The 2026 OPPS/ASC Final Rule is expected to lift restrictions on higher-acuity procedures, such as cardiac ablation, enabling more care to move out of traditional hospital settings. This is part of a broader reimbursement and demand trend toward lower-cost, more accessible care.

For medtech companies, this migration requires a complete rethinking of commercial strategies. Sales forces that once targeted hospital supply chain executives must now engage with ASC administrators and physician-owners who are more price-sensitive and efficiency-driven. Product design assumptions also change: devices used in ASCs may need to be more portable, easier to use, and compatible with smaller footprint infrastructure. The economic value proposition similarly shifts, with greater emphasis on reducing procedure time and avoiding readmissions—metrics that resonate with outpatient facilities.

Moreover, this trend is not confined to the United States. Many European and Asian health systems are advancing day-surgery programs, creating a global need for medtech companies to segment their offerings by site of care.

3. Supply Chain Resilience and Manufacturing Realignment

Global trade tensions, tariff exposure, and residual pandemic-era bottlenecks have transformed supply chain reliability from an operational concern into a strategic imperative. Medtech firms are reviewing their sourcing of critical components, from semiconductors to specialized metals, and rethinking their manufacturing footprints. The era of single-country production for global markets is over.

The trend is toward multi-region manufacturing, often with additional capacity in Southeast Asia, Latin America, or Eastern Europe as complements to existing hubs. Larger firms are leveraging scale and vertical integration to buffer against volatility, while smaller players may need to form alliances or adopt modular production approaches. The competitive implications are significant: a company that can guarantee supply continuity while competitors face shortages will win market share, especially in essential medical devices.

Tariff dynamics also affect pricing strategies. Companies may need to absorb costs or pass them to customers, but in a pricing-sensitive environment—exacerbated by the VBP trend in China—this is not straightforward. Strategic flexibility in sourcing and production is thus a source of competitive advantage.

4. GLP-1 Therapies: A Disrupter Across Adjacent Markets

The extraordinary commercial success of GLP-1 receptor agonists (used to treat diabetes and obesity) is generating ripple effects across medtech. While bariatric surgery remains the most effective intervention for severe obesity, the growing use of GLP-1 drugs is changing patient referral patterns and delaying or reducing demand for certain surgical procedures. Clarivate's analysis notes that not all bariatric procedures are affected equally, with more invasive, higher-risk surgeries feeling sharper volume pressure. Conversely, the expansion of metabolic therapy may create new opportunities for devices supporting weight management, such as endoscopic bariatric tools or continuous glucose monitors.

Additionally, the systemic effects of GLP-1 therapies—on cardiovascular risk, sleep apnea, and kidney disease—are blurring traditional therapy boundaries. Medtech firms in cardiology, renal care, and respiratory markets must now track pharmaceutical advances and anticipate how downstream interventional volumes might change. This cross-sector impact demands that medtech strategy incorporates a pharmaco-economic perspective, a novelty for many device makers.

5. Platform-Based Competition and Enabling Technologies

Robotics, advanced imaging, navigation systems, and digital workflow software are no longer nice-to-have additions to surgical tools; they are becoming the central architecture of modern procedure suites. Medtech companies are increasingly competing not through individual devices, but through integrated platforms that span preoperative planning, intraoperative execution, and postoperative care. These platforms generate data that can improve outcomes, streamline workflows, and create lock-in effects that deepen customer relationships.

Open-platform systems are complicating the picture, however. While they expand customer choice, they also commoditize individual components and require companies to differentiate at the software and integration layer. The result is a competitive environment where intelligence and data analytics are as important as hardware. Companies that fail to invest in platform capabilities risk becoming peripheral suppliers, while those that build comprehensive ecosystems can capture disproportionate value.

Commercial Impact

These trends are redefining market opportunities and threats. For businesses, the most pressing implications include:

• Pricing pressure and margin erosion in markets exposed to VBP and ASC price sensitivity, forcing companies to optimize value propositions and cost structures.
• Portfolio rebalancing away from products that are heavily impacted by GLP-1 substitution and toward high-growth categories such as robotic-assisted surgery and digital health.
• Manufacturing flexibility as a key competitive criterion, with investment in resilient supply chains becoming a board-level priority.
• New customer segmentation by site of care, requiring to go-to-market models tailored to hospitals, ASCs, and increasingly home-based care.
• Data-driven differentiation as enabling technologies create opportunities for new service lines, remote monitoring, and outcome-based contracts.

For global markets, these shifts may influence where medtech innovation occurs and who captures the resulting economic benefits. China's domestic industry gains, while multinationals reassess their investment. The outpatient migration could accelerate procedure growth and improve access in underserved areas, but it also pressures reimbursement systems. Trade policies might alter the geography of production and trade flows, with significant implications for countries dependent on medical device exports.

Strategic Insights

Executives and corporate strategists should consider the following actionable insights as they adapt to these trends:

• Decouple pricing from historical anchors: In markets where procurement reforms set new price baselines, firms to need to build value-based arguments that justify premium pricing through improved outcomes and total cost efficiency. This will require stronger health economics data and real-world evidence.
• Adopt a site-of-care lens: Rather than treating ASCs as an extension of hospital markets, companies should design dedicated products, pricing, and services for outpatient settings. This may involve simplifying device usability, reducing capital costs, and providing training for a wider range of clinicians.
• Invest in supply chain analytics: Use advanced forecasting and analytics to create resilience while managing inventory costs. Dual-sourcing of critical materials and products should be standard practice, and technology investment should be aimed at transparency across the entire supply network.
• Monitor pharma-medtech convergence: Keep close watch on the adoption curves of high-impact therapies like GLP-1s and model scenarios for their effect on procedure volumes. Consider partnerships or adjacent investments that can hedge against procedural shifts.
• Build ecosystem partnerships: No single company can control all layers of the platform stack. Strategic alliances with software providers, imaging specialists, or data analytics firms can accelerate platform development without requiring massive internal R&D budgets.

Future Outlook

Looking forward to the next 3–10 years, these trends are likely to intensify and intersect. The expansion of value-based healthcare models—already visible in China's VBP and US Medicare’s move toward episode-based payment—may become the global norm, making demonstrated economic value even more essential to market access.

Advances in artificial intelligence will further enable platform-based competition, as surgical robots and imaging systems become increasingly autonomous and data-driven. The GLP-1 story is still in its early chapters, and new indications, delivery forms (e.g., oral medications), and combinations with digital therapeutics could broaden the impact on medical devices, both negatively and positively.

Supply chains will likely become more regionalized, with companies maintaining hubs in the Americas, Europe, and Asia to serve local markets and mitigate geopolitical risk. This could raise production costs but also drive diversification and resilience. In parallel, domestic procurement and industrial policies in countries like the United States and members of the European Union may reduce dependence on Asian manufacturing, further shifting trade flows.

The medtech industry of 2030 will be more concentrated, more data-centric, and more attuned to the economics of healthcare delivery. Companies that start today to adapt their strategies to these five trends will be better positioned to lead the next decade of growth.

Conclusion

The forces outlined in Clarivate's Medtech Trends to Watch 2026 are not speculative; they are observable in real-time regulatory actions, commercial performance, and technology investment. While the specific data points may evolve as new reports are released, the strategic direction is clear: the medtech industry is moving toward a model where pricing is disciplined, sites of care are diverse, supply chains are resilient, pharmaceutical interactions are inevitable, and technology platforms are central to competitive differentiation.

For corporate leaders, the imperative is to look beyond quarterly results and embrace a broader, more integrated view of the industry. Those who do will not only survive the turbulence but also define the future of modern healthcare.